Straits Times Index
3,137.54 +25.89 (+0.83%) Nikkei
26,931.39 +60.12 (+0.22%) Hang Seng
22,229.52 +510.46 (+2.35%) FTSE 100
7,258.32 +49.51 (+0.69%) BTC-USD
20,771.87 -280.21 (-1.33%) CMC Crypto 200
451.95 -9.84 (-2.13%)
Coherus BioSciences, Inc. (CHRS)
After hours:
| Previous close | 7.50 |
| Open | 7.53 |
| Bid | 7.64 x 4000 |
| Ask | 7.87 x 2900 |
| Day's range | 7.42 - 7.76 |
| 52-week range | 5.60 - 19.32 |
| Volume | |
| Avg. volume | 1,048,595 |
| Market cap | 590.737M |
| Beta (5Y monthly) | 1.21 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.75 |
| Earnings date | 03 Aug 2022 - 08 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 19.57 |
- Zacks
Swedish Orphan Biovitrum (BIOVF) Stock Jumps 5.3%: Will It Continue to Soar?
Swedish Orphan Biovitrum (BIOVF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Motley Fool
Coherus BioSciences (CHRS) Q1 2022 Earnings Call Transcript
Today's call includes forward-looking statements regarding Coherus' current expectations about future events. All these future events involve substantial risks and uncertainties that are beyond our control and could cause actual results, performance, or achievements to differ from the results, performance, or achievements implied by the forward-looking statements.
- Zacks
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -55% and 11.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
